#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4 .
1-1	0-1	4	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=In the present study , we performed 16s rRNA deep sequencing and obtained large amounts of data concerning the microbial composition , diversity , and abundance in healthy subjects and RA patients with various clinical phenotypes .
3-1	15-17	In	_	_	_	_
3-2	18-21	the	abstract[3]	new[3]	coref	12-22[86_3]
3-3	22-29	present	abstract[3]	new[3]	_	_
3-4	30-35	study	abstract[3]	new[3]	_	_
3-5	36-37	,	_	_	_	_
3-6	38-40	we	person	acc	ana	9-1
3-7	41-50	performed	_	_	_	_
3-8	51-54	16s	_	_	_	_
3-9	55-59	rRNA	abstract|abstract[6]	new|new[6]	_	_
3-10	60-64	deep	abstract[6]	new[6]	_	_
3-11	65-75	sequencing	abstract[6]	new[6]	_	_
3-12	76-79	and	_	_	_	_
3-13	80-88	obtained	_	_	_	_
3-14	89-94	large	quantity[7]	new[7]	_	_
3-15	95-102	amounts	quantity[7]	new[7]	_	_
3-16	103-105	of	quantity[7]	new[7]	_	_
3-17	106-110	data	quantity[7]|abstract	new[7]|new	_	_
3-18	111-121	concerning	_	_	_	_
3-19	122-125	the	abstract[9]	new[9]	coref	8-7[59_9]
3-20	126-135	microbial	abstract[9]	new[9]	_	_
3-21	136-147	composition	abstract[9]	new[9]	_	_
3-22	148-149	,	_	_	_	_
3-23	150-159	diversity	abstract	new	_	_
3-24	160-161	,	_	_	_	_
3-25	162-165	and	_	_	_	_
3-26	166-175	abundance	abstract[11]	new[11]	coref	4-6[18_11]
3-27	176-178	in	abstract[11]	new[11]	_	_
3-28	179-186	healthy	abstract[11]|person[12]|person[13]	new[11]|new[12]|new[13]	coref|coref|coref|coref	4-19[23_12]|16-8[111_13]|4-19[23_12]|16-8[111_13]
3-29	187-195	subjects	abstract[11]|person[12]|person[13]	new[11]|new[12]|new[13]	_	_
3-30	196-199	and	abstract[11]|person[13]	new[11]|new[13]	_	_
3-31	200-202	RA	abstract[11]|person[13]|organization|person[15]	new[11]|new[13]|new|new[15]	coref|coref|coref|coref	4-15|4-15[22_15]|4-15|4-15[22_15]
3-32	203-211	patients	abstract[11]|person[13]|person[15]	new[11]|new[13]|new[15]	_	_
3-33	212-216	with	abstract[11]|person[13]|person[15]	new[11]|new[13]|new[15]	_	_
3-34	217-224	various	abstract[11]|person[13]|person[15]|abstract[16]	new[11]|new[13]|new[15]|new[16]	coref	5-29[37_16]
3-35	225-233	clinical	abstract[11]|person[13]|person[15]|abstract[16]	new[11]|new[13]|new[15]|new[16]	_	_
3-36	234-244	phenotypes	abstract[11]|person[13]|person[15]|abstract[16]	new[11]|new[13]|new[15]|new[16]	_	_
3-37	245-246	.	_	_	_	_

#Text=The results have demonstrated that a lower abundance and evenness of gut microbiota in RA patients compared with healthy subjects , with α-diversity lower in RF-positive or ACPA-positive RA patients than healthy subjects .
4-1	247-250	The	abstract[17]	new[17]	coref	20-4[161_17]
4-2	251-258	results	abstract[17]	new[17]	_	_
4-3	259-263	have	_	_	_	_
4-4	264-276	demonstrated	_	_	_	_
4-5	277-281	that	_	_	_	_
4-6	282-283	a	abstract[18]	giv[18]	coref	7-15[51_18]
4-7	284-289	lower	abstract[18]	giv[18]	_	_
4-8	290-299	abundance	abstract[18]	giv[18]	_	_
4-9	300-303	and	_	_	_	_
4-10	304-312	evenness	abstract[19]	new[19]	_	_
4-11	313-315	of	abstract[19]	new[19]	_	_
4-12	316-319	gut	abstract[19]|substance[20]	new[19]|new[20]	coref	5-15[33_20]
4-13	320-330	microbiota	abstract[19]|substance[20]	new[19]|new[20]	_	_
4-14	331-333	in	abstract[19]|substance[20]	new[19]|new[20]	_	_
4-15	334-336	RA	abstract[19]|substance[20]|organization|person[22]	new[19]|new[20]|giv|giv[22]	coref|coref|coref|coref	4-29|4-26[27_22]|4-29|4-26[27_22]
4-16	337-345	patients	abstract[19]|substance[20]|person[22]	new[19]|new[20]|giv[22]	_	_
4-17	346-354	compared	abstract[19]	new[19]	_	_
4-18	355-359	with	abstract[19]	new[19]	_	_
4-19	360-367	healthy	abstract[19]|quantity[23]	new[19]|giv[23]	coref	4-32[28_23]
4-20	368-376	subjects	abstract[19]|quantity[23]	new[19]|giv[23]	_	_
4-21	377-378	,	abstract[19]	new[19]	_	_
4-22	379-383	with	abstract[19]	new[19]	_	_
4-23	384-395	α-diversity	abstract[19]|abstract[24]	new[19]|new[24]	coref	9-11[66_24]
4-24	396-401	lower	abstract[19]|abstract[24]	new[19]|new[24]	_	_
4-25	402-404	in	abstract[19]|abstract[24]	new[19]|new[24]	_	_
4-26	405-416	RF-positive	abstract[19]|abstract[24]|abstract|person[27]	new[19]|new[24]|new|giv[27]	coref|coref|coref|coref	5-26[36_27]|15-5|5-26[36_27]|15-5
4-27	417-419	or	abstract[19]|abstract[24]|person[27]	new[19]|new[24]|giv[27]	_	_
4-28	420-433	ACPA-positive	abstract[19]|abstract[24]|person[27]	new[19]|new[24]|giv[27]	_	_
4-29	434-436	RA	abstract[19]|abstract[24]|organization|person[27]	new[19]|new[24]|giv|giv[27]	coref	5-26
4-30	437-445	patients	abstract[19]|abstract[24]|person[27]	new[19]|new[24]|giv[27]	_	_
4-31	446-450	than	abstract[19]|abstract[24]|person[27]	new[19]|new[24]|giv[27]	_	_
4-32	451-458	healthy	abstract[19]|abstract[24]|person[27]|person[28]	new[19]|new[24]|giv[27]|giv[28]	coref	5-18[34_28]
4-33	459-467	subjects	abstract[19]|abstract[24]|person[27]|person[28]	new[19]|new[24]|giv[27]|giv[28]	_	_
4-34	468-469	.	_	_	_	_

#Text=Using the permutational multivariate analysis of variance ( PERMANOVA ) , the β-diversity of gut microbiota in healthy subjects was significantly different from that in RA patients with different phenotypes .
5-1	470-475	Using	_	_	_	_
5-2	476-479	the	abstract[29]	new[29]	coref	16-14[115_29]
5-3	480-493	permutational	abstract[29]	new[29]	_	_
5-4	494-506	multivariate	abstract[29]	new[29]	_	_
5-5	507-515	analysis	abstract[29]	new[29]	_	_
5-6	516-518	of	abstract[29]	new[29]	_	_
5-7	519-527	variance	abstract[29]|abstract	new[29]|new	appos	5-9
5-8	528-529	(	_	_	_	_
5-9	530-539	PERMANOVA	abstract	giv	coref	16-15
5-10	540-541	)	_	_	_	_
5-11	542-543	,	_	_	_	_
5-12	544-547	the	quantity[32]	new[32]	coref	16-5[109_32]
5-13	548-559	β-diversity	quantity[32]	new[32]	_	_
5-14	560-562	of	quantity[32]	new[32]	_	_
5-15	563-566	gut	quantity[32]|substance[33]	new[32]|giv[33]	coref	10-5[75_33]
5-16	567-577	microbiota	quantity[32]|substance[33]	new[32]|giv[33]	_	_
5-17	578-580	in	quantity[32]|substance[33]	new[32]|giv[33]	_	_
5-18	581-588	healthy	quantity[32]|substance[33]|person[34]	new[32]|giv[33]|giv[34]	coref	6-15[44_34]
5-19	589-597	subjects	quantity[32]|substance[33]|person[34]	new[32]|giv[33]|giv[34]	_	_
5-20	598-601	was	_	_	_	_
5-21	602-615	significantly	_	_	_	_
5-22	616-625	different	_	_	_	_
5-23	626-630	from	_	_	_	_
5-24	631-635	that	_	_	_	_
5-25	636-638	in	_	_	_	_
5-26	639-641	RA	organization|person[36]	giv|giv[36]	coref|coref|coref|coref	6-11|6-11[43_36]|6-11|6-11[43_36]
5-27	642-650	patients	person[36]	giv[36]	_	_
5-28	651-655	with	person[36]	giv[36]	_	_
5-29	656-665	different	person[36]|abstract[37]	giv[36]|giv[37]	coref	13-25[94_37]
5-30	666-676	phenotypes	person[36]|abstract[37]	giv[36]|giv[37]	_	_
5-31	677-678	.	_	_	_	_

#Text=The phylum Verrucomicrobiae and genus Akkermansia were more abundant in RA patients compared with healthy subjects .
6-1	679-682	The	object[39]	new[39]	coref	19-22[153_39]
6-2	683-689	phylum	person|object[39]	new|new[39]	coref	7-20
6-3	690-706	Verrucomicrobiae	object[39]	new[39]	_	_
6-4	707-710	and	_	_	_	_
6-5	711-716	genus	abstract|abstract[41]	new|new[41]	coref|coref|coref|coref	19-31|19-30[155_41]|19-31|19-30[155_41]
6-6	717-728	Akkermansia	abstract[41]	new[41]	_	_
6-7	729-733	were	_	_	_	_
6-8	734-738	more	_	_	_	_
6-9	739-747	abundant	_	_	_	_
6-10	748-750	in	_	_	_	_
6-11	751-753	RA	organization|person[43]	giv|giv[43]	coref|coref|coref|coref	7-2|7-2[46_43]|7-2|7-2[46_43]
6-12	754-762	patients	person[43]	giv[43]	_	_
6-13	763-771	compared	_	_	_	_
6-14	772-776	with	_	_	_	_
6-15	777-784	healthy	person[44]	giv[44]	coref	9-19[69_44]
6-16	785-793	subjects	person[44]	giv[44]	_	_
6-17	794-795	.	_	_	_	_

#Text=Among RA patients , those with higher levels of TNF-α or IL-17A had increased the relative abundance of the phylum Gammaproteobacteria compared to those with lower cytokine levels .
7-1	796-801	Among	_	_	_	_
7-2	802-804	RA	organization|person[46]	giv|giv[46]	coref|coref|coref|coref	8-4|8-4[58_46]|8-4|8-4[58_46]
7-3	805-813	patients	person[46]	giv[46]	_	_
7-4	814-815	,	_	_	_	_
7-5	816-821	those	person[47]	acc[47]	ana	7-24[54_47]
7-6	822-826	with	person[47]	acc[47]	_	_
7-7	827-833	higher	person[47]|abstract[48]	acc[47]|new[48]	_	_
7-8	834-840	levels	person[47]|abstract[48]	acc[47]|new[48]	_	_
7-9	841-843	of	person[47]|abstract[48]	acc[47]|new[48]	_	_
7-10	844-849	TNF-α	person[47]|abstract[48]|abstract	acc[47]|new[48]|new	coref	18-21
7-11	850-852	or	person[47]|abstract[48]	acc[47]|new[48]	_	_
7-12	853-859	IL-17A	person[47]|abstract[48]|abstract	acc[47]|new[48]|new	coref	18-23
7-13	860-863	had	_	_	_	_
7-14	864-873	increased	_	_	_	_
7-15	874-877	the	abstract[51]	giv[51]	coref	17-10[0_51]
7-16	878-886	relative	abstract[51]	giv[51]	_	_
7-17	887-896	abundance	abstract[51]	giv[51]	_	_
7-18	897-899	of	abstract[51]	giv[51]	_	_
7-19	900-903	the	abstract[51]|substance[53]	giv[51]|new[53]	_	_
7-20	904-910	phylum	abstract[51]|person|substance[53]	giv[51]|giv|new[53]	coref	19-22
7-21	911-930	Gammaproteobacteria	abstract[51]|substance[53]	giv[51]|new[53]	_	_
7-22	931-939	compared	_	_	_	_
7-23	940-942	to	_	_	_	_
7-24	943-948	those	person[54]	giv[54]	_	_
7-25	949-953	with	person[54]	giv[54]	_	_
7-26	954-959	lower	person[54]|abstract[56]	giv[54]|new[56]	_	_
7-27	960-968	cytokine	person[54]|abstract|abstract[56]	giv[54]|new|new[56]	_	_
7-28	969-975	levels	person[54]|abstract[56]	giv[54]|new[56]	_	_
7-29	976-977	.	_	_	_	_

#Text=In addition , RA patients exhibited a different microbial composition which was related to RF/ACPA seropositivity .
8-1	978-980	In	_	_	_	_
8-2	981-989	addition	_	_	_	_
8-3	990-991	,	_	_	_	_
8-4	992-994	RA	organization|person[58]	giv|giv[58]	coref|coref|coref|coref	9-2|9-1[64_58]|9-2|9-1[64_58]
8-5	995-1003	patients	person[58]	giv[58]	_	_
8-6	1004-1013	exhibited	_	_	_	_
8-7	1014-1015	a	abstract[59]	giv[59]	coref	18-29[142_59]
8-8	1016-1025	different	abstract[59]	giv[59]	_	_
8-9	1026-1035	microbial	abstract[59]	giv[59]	_	_
8-10	1036-1047	composition	abstract[59]	giv[59]	_	_
8-11	1048-1053	which	_	_	_	_
8-12	1054-1057	was	_	_	_	_
8-13	1058-1065	related	_	_	_	_
8-14	1066-1068	to	_	_	_	_
8-15	1069-1076	RF/ACPA	abstract|abstract[61]	new|new[61]	coref|coref	16-29|16-29
8-16	1077-1091	seropositivity	abstract[61]	new[61]	_	_
8-17	1092-1093	.	_	_	_	_

#Text=Our RA patients in either active or inactive status had a lower α-diversity of gut microbial taxa than healthy subjects , consistent with the findings in Korean patients with early RA .
9-1	1094-1097	Our	person|person[64]	giv|giv[64]	coref|ana|coref|ana	9-27[71_64]|13-1|9-27[71_64]|13-1
9-2	1098-1100	RA	organization|person[64]	giv|giv[64]	coref	9-30[72_0]
9-3	1101-1109	patients	person[64]	giv[64]	_	_
9-4	1110-1112	in	person[64]	giv[64]	_	_
9-5	1113-1119	either	person[64]|abstract[65]	giv[64]|new[65]	coref	16-29[121_65]
9-6	1120-1126	active	person[64]|abstract[65]	giv[64]|new[65]	_	_
9-7	1127-1129	or	person[64]|abstract[65]	giv[64]|new[65]	_	_
9-8	1130-1138	inactive	person[64]|abstract[65]	giv[64]|new[65]	_	_
9-9	1139-1145	status	person[64]|abstract[65]	giv[64]|new[65]	_	_
9-10	1146-1149	had	_	_	_	_
9-11	1150-1151	a	abstract[66]	giv[66]	_	_
9-12	1152-1157	lower	abstract[66]	giv[66]	_	_
9-13	1158-1169	α-diversity	abstract[66]	giv[66]	_	_
9-14	1170-1172	of	abstract[66]	giv[66]	_	_
9-15	1173-1176	gut	abstract[66]	giv[66]	_	_
9-16	1177-1186	microbial	abstract[66]|abstract|abstract[68]	giv[66]|new|new[68]	coref|coref	22-24|22-24
9-17	1187-1191	taxa	abstract[66]|abstract[68]	giv[66]|new[68]	_	_
9-18	1192-1196	than	abstract[66]|abstract[68]	giv[66]|new[68]	_	_
9-19	1197-1204	healthy	abstract[66]|abstract[68]|person[69]	giv[66]|new[68]|giv[69]	coref	16-8[110_69]
9-20	1205-1213	subjects	abstract[66]|abstract[68]|person[69]	giv[66]|new[68]|giv[69]	_	_
9-21	1214-1215	,	_	_	_	_
9-22	1216-1226	consistent	_	_	_	_
9-23	1227-1231	with	_	_	_	_
9-24	1232-1235	the	abstract[70]	new[70]	coref	12-2[79_70]
9-25	1236-1244	findings	abstract[70]	new[70]	_	_
9-26	1245-1247	in	abstract[70]	new[70]	_	_
9-27	1248-1254	Korean	abstract[70]|person[71]	new[70]|giv[71]	coref	10-10[76_71]
9-28	1255-1263	patients	abstract[70]|person[71]	new[70]|giv[71]	_	_
9-29	1264-1268	with	abstract[70]|person[71]	new[70]|giv[71]	_	_
9-30	1269-1274	early	abstract[70]|person[71]|organization[72]	new[70]|giv[71]|giv[72]	coref	12-15[0_72]
9-31	1275-1277	RA	abstract[70]|person[71]|organization[72]	new[70]|giv[71]|giv[72]	_	_
9-32	1278-1279	.	_	_	_	_

#Text=Moreover , α-diversity of gut microbiota was lower in ACPA-positive patients compared to HC .
10-1	1280-1288	Moreover	_	_	_	_
10-2	1289-1290	,	_	_	_	_
10-3	1291-1302	α-diversity	abstract[73]	new[73]	coref	12-9[0_73]
10-4	1303-1305	of	abstract[73]	new[73]	_	_
10-5	1306-1309	gut	abstract[73]|abstract|substance[75]	new[73]|new|giv[75]	coref|coref|coref|coref	18-29|18-30[0_75]|18-29|18-30[0_75]
10-6	1310-1320	microbiota	abstract[73]|substance[75]	new[73]|giv[75]	_	_
10-7	1321-1324	was	_	_	_	_
10-8	1325-1330	lower	_	_	_	_
10-9	1331-1333	in	_	_	_	_
10-10	1334-1347	ACPA-positive	person[76]	giv[76]	coref	12-14[85_76]
10-11	1348-1356	patients	person[76]	giv[76]	_	_
10-12	1357-1365	compared	_	_	_	_
10-13	1366-1368	to	_	_	_	_
10-14	1369-1371	HC	abstract	new	_	_
10-15	1372-1373	.	_	_	_	_

#Text=Although Chen et al.
11-1	1374-1382	Although	_	_	_	_
11-2	1383-1387	Chen	person	new	coref	26-30
11-3	1388-1390	et	_	_	_	_
11-4	1391-1394	al.	_	_	_	_

#Text=revealed similar findings , the significant association of α-diversity with ACPA positivity in their RA patients could not be reproduced in the present study .
12-1	1395-1403	revealed	_	_	_	_
12-2	1404-1411	similar	abstract[79]	giv[79]	coref	20-1[160_79]
12-3	1412-1420	findings	abstract[79]	giv[79]	_	_
12-4	1421-1422	,	_	_	_	_
12-5	1423-1426	the	abstract[80]	new[80]	_	_
12-6	1427-1438	significant	abstract[80]	new[80]	_	_
12-7	1439-1450	association	abstract[80]	new[80]	_	_
12-8	1451-1453	of	abstract[80]	new[80]	_	_
12-9	1454-1465	α-diversity	abstract[80]|abstract	new[80]|giv	coref	15-14[105_0]
12-10	1466-1470	with	abstract[80]	new[80]	_	_
12-11	1471-1475	ACPA	abstract[80]|organization|abstract[83]	new[80]|new|new[83]	coref|coref	14-7|14-7
12-12	1476-1486	positivity	abstract[80]|abstract[83]	new[80]|new[83]	_	_
12-13	1487-1489	in	abstract[80]|abstract[83]	new[80]|new[83]	_	_
12-14	1490-1495	their	abstract[80]|abstract[83]|person[85]	new[80]|new[83]|giv[85]	coref	15-7[103_85]
12-15	1496-1498	RA	abstract[80]|abstract[83]|organization|person[85]	new[80]|new[83]|giv|giv[85]	coref	13-22
12-16	1499-1507	patients	abstract[80]|abstract[83]|person[85]	new[80]|new[83]|giv[85]	_	_
12-17	1508-1513	could	_	_	_	_
12-18	1514-1517	not	_	_	_	_
12-19	1518-1520	be	_	_	_	_
12-20	1521-1531	reproduced	_	_	_	_
12-21	1532-1534	in	_	_	_	_
12-22	1535-1538	the	abstract[86]	giv[86]	coref	26-23[222_86]
12-23	1539-1546	present	abstract[86]	giv[86]	_	_
12-24	1547-1552	study	abstract[86]	giv[86]	_	_
12-25	1553-1554	.	_	_	_	_

#Text=Our statistical data has suggested that there was no significant difference which may be due to the small sample size of RA subgroups with different phenotypes .
13-1	1555-1558	Our	person|abstract[88]	giv|new[88]	ana|ana	19-16|19-16
13-2	1559-1570	statistical	abstract[88]	new[88]	_	_
13-3	1571-1575	data	abstract[88]	new[88]	_	_
13-4	1576-1579	has	_	_	_	_
13-5	1580-1589	suggested	_	_	_	_
13-6	1590-1594	that	_	_	_	_
13-7	1595-1600	there	_	_	_	_
13-8	1601-1604	was	_	_	_	_
13-9	1605-1607	no	abstract[89]	new[89]	coref	16-2[108_89]
13-10	1608-1619	significant	abstract[89]	new[89]	_	_
13-11	1620-1630	difference	abstract[89]	new[89]	_	_
13-12	1631-1636	which	_	_	_	_
13-13	1637-1640	may	_	_	_	_
13-14	1641-1643	be	_	_	_	_
13-15	1644-1647	due	_	_	_	_
13-16	1648-1650	to	_	_	_	_
13-17	1651-1654	the	abstract[91]	new[91]	_	_
13-18	1655-1660	small	abstract[91]	new[91]	_	_
13-19	1661-1667	sample	object|abstract[91]	new|new[91]	_	_
13-20	1668-1672	size	abstract[91]	new[91]	_	_
13-21	1673-1675	of	abstract[91]	new[91]	_	_
13-22	1676-1678	RA	abstract[91]|organization|abstract[93]	new[91]|giv|new[93]	coref|coref	16-11|16-11
13-23	1679-1688	subgroups	abstract[91]|abstract[93]	new[91]|new[93]	_	_
13-24	1689-1693	with	abstract[91]|abstract[93]	new[91]|new[93]	_	_
13-25	1694-1703	different	abstract[91]|abstract[93]|abstract[94]	new[91]|new[93]|giv[94]	coref	16-22[0_94]
13-26	1704-1714	phenotypes	abstract[91]|abstract[93]|abstract[94]	new[91]|new[93]|giv[94]	_	_
13-27	1715-1716	.	_	_	_	_

#Text=In addition , the production of ACPA may be multifactorial , such as genetic factor , smoking , and the severity of periodontitis .
14-1	1717-1719	In	_	_	_	_
14-2	1720-1728	addition	_	_	_	_
14-3	1729-1730	,	_	_	_	_
14-4	1731-1734	the	abstract[95]	new[95]	_	_
14-5	1735-1745	production	abstract[95]	new[95]	_	_
14-6	1746-1748	of	abstract[95]	new[95]	_	_
14-7	1749-1753	ACPA	abstract[95]|abstract	new[95]|giv	_	_
14-8	1754-1757	may	_	_	_	_
14-9	1758-1760	be	_	_	_	_
14-10	1761-1775	multifactorial	_	_	_	_
14-11	1776-1777	,	_	_	_	_
14-12	1778-1782	such	_	_	_	_
14-13	1783-1785	as	_	_	_	_
14-14	1786-1793	genetic	abstract[97]	new[97]	_	_
14-15	1794-1800	factor	abstract[97]	new[97]	_	_
14-16	1801-1802	,	_	_	_	_
14-17	1803-1810	smoking	abstract	new	_	_
14-18	1811-1812	,	_	_	_	_
14-19	1813-1816	and	_	_	_	_
14-20	1817-1820	the	abstract[99]	new[99]	_	_
14-21	1821-1829	severity	abstract[99]	new[99]	_	_
14-22	1830-1832	of	abstract[99]	new[99]	_	_
14-23	1833-1846	periodontitis	abstract[99]|abstract	new[99]|new	_	_
14-24	1847-1848	.	_	_	_	_

#Text=After the pooling of RF-positive and ACPA-positive patients in a single goup , a significantly lower α-diversity was observed in seropositive patients compared to seronegative patients .
15-1	1849-1854	After	_	_	_	_
15-2	1855-1858	the	abstract[101]	new[101]	_	_
15-3	1859-1866	pooling	abstract[101]	new[101]	_	_
15-4	1867-1869	of	abstract[101]	new[101]	_	_
15-5	1870-1881	RF-positive	abstract[101]|abstract	new[101]|giv	_	_
15-6	1882-1885	and	_	_	_	_
15-7	1886-1899	ACPA-positive	person[103]	giv[103]	coref	15-21[106_103]
15-8	1900-1908	patients	person[103]	giv[103]	_	_
15-9	1909-1911	in	person[103]	giv[103]	_	_
15-10	1912-1913	a	person[103]|abstract[104]	giv[103]|new[104]	_	_
15-11	1914-1920	single	person[103]|abstract[104]	giv[103]|new[104]	_	_
15-12	1921-1925	goup	person[103]|abstract[104]	giv[103]|new[104]	_	_
15-13	1926-1927	,	_	_	_	_
15-14	1928-1929	a	abstract[105]	giv[105]	_	_
15-15	1930-1943	significantly	abstract[105]	giv[105]	_	_
15-16	1944-1949	lower	abstract[105]	giv[105]	_	_
15-17	1950-1961	α-diversity	abstract[105]	giv[105]	_	_
15-18	1962-1965	was	_	_	_	_
15-19	1966-1974	observed	_	_	_	_
15-20	1975-1977	in	_	_	_	_
15-21	1978-1990	seropositive	person[106]	giv[106]	coref	15-25[107_106]
15-22	1991-1999	patients	person[106]	giv[106]	_	_
15-23	2000-2008	compared	_	_	_	_
15-24	2009-2011	to	_	_	_	_
15-25	2012-2024	seronegative	person[107]	giv[107]	coref	16-11[113_107]
15-26	2025-2033	patients	person[107]	giv[107]	_	_
15-27	2034-2035	.	_	_	_	_

#Text=Regarding the difference in the β-diversity between healthy subjects and RA patients , the PERMANOVA analysis showed a significant difference in phenotypes characterized by different disease activity and RF/ACPA status ( Table 2 ) .
16-1	2036-2045	Regarding	_	_	_	_
16-2	2046-2049	the	abstract[108]	giv[108]	coref	16-18[116_108]
16-3	2050-2060	difference	abstract[108]	giv[108]	_	_
16-4	2061-2063	in	abstract[108]	giv[108]	_	_
16-5	2064-2067	the	abstract[108]|quantity[109]	giv[108]|giv[109]	coref	18-9[134_109]
16-6	2068-2079	β-diversity	abstract[108]|quantity[109]	giv[108]|giv[109]	_	_
16-7	2080-2087	between	abstract[108]|quantity[109]	giv[108]|giv[109]	_	_
16-8	2088-2095	healthy	abstract[108]|quantity[109]|person[110]|person[111]	giv[108]|giv[109]|giv[110]|giv[111]	coref|coref	17-21[131_110]|17-21[131_110]
16-9	2096-2104	subjects	abstract[108]|quantity[109]|person[110]|person[111]	giv[108]|giv[109]|giv[110]|giv[111]	_	_
16-10	2105-2108	and	abstract[108]|quantity[109]|person[111]	giv[108]|giv[109]|giv[111]	_	_
16-11	2109-2111	RA	abstract[108]|quantity[109]|person[111]|organization|person[113]	giv[108]|giv[109]|giv[111]|giv|giv[113]	coref|coref|coref|coref	17-18|17-18[130_113]|17-18|17-18[130_113]
16-12	2112-2120	patients	abstract[108]|quantity[109]|person[111]|person[113]	giv[108]|giv[109]|giv[111]|giv[113]	_	_
16-13	2121-2122	,	_	_	_	_
16-14	2123-2126	the	abstract[115]	giv[115]	_	_
16-15	2127-2136	PERMANOVA	abstract|abstract[115]	giv|giv[115]	_	_
16-16	2137-2145	analysis	abstract[115]	giv[115]	_	_
16-17	2146-2152	showed	_	_	_	_
16-18	2153-2154	a	abstract[116]	giv[116]	coref	17-9[127_116]
16-19	2155-2166	significant	abstract[116]	giv[116]	_	_
16-20	2167-2177	difference	abstract[116]	giv[116]	_	_
16-21	2178-2180	in	abstract[116]	giv[116]	_	_
16-22	2181-2191	phenotypes	abstract[116]|abstract	giv[116]|giv	_	_
16-23	2192-2205	characterized	_	_	_	_
16-24	2206-2208	by	_	_	_	_
16-25	2209-2218	different	abstract[119]	new[119]	_	_
16-26	2219-2226	disease	abstract|abstract[119]	new|new[119]	_	_
16-27	2227-2235	activity	abstract[119]	new[119]	_	_
16-28	2236-2239	and	_	_	_	_
16-29	2240-2247	RF/ACPA	organization|abstract[121]	giv|giv[121]	_	_
16-30	2248-2254	status	abstract[121]	giv[121]	_	_
16-31	2255-2256	(	_	_	_	_
16-32	2257-2262	Table	abstract[122]	new[122]	_	_
16-33	2263-2264	2	abstract[122]	new[122]	_	_
16-34	2265-2266	)	_	_	_	_
16-35	2267-2268	.	_	_	_	_

#Text=The weighted UniFrac distance , qualitative measurement of phylogenetic abundance difference , showed a statistical significance between RA patients and healthy subjects .
17-1	2269-2272	The	abstract[124]	new[124]	appos	17-6[125_124]
17-2	2273-2281	weighted	abstract[124]	new[124]	_	_
17-3	2282-2289	UniFrac	event|abstract[124]	new|new[124]	_	_
17-4	2290-2298	distance	abstract[124]	new[124]	_	_
17-5	2299-2300	,	_	_	_	_
17-6	2301-2312	qualitative	abstract[125]	giv[125]	_	_
17-7	2313-2324	measurement	abstract[125]	giv[125]	_	_
17-8	2325-2327	of	abstract[125]	giv[125]	_	_
17-9	2328-2340	phylogenetic	abstract[125]|abstract[127]	giv[125]|giv[127]	coref	18-6[0_127]
17-10	2341-2350	abundance	abstract[125]|abstract|abstract[127]	giv[125]|giv|giv[127]	_	_
17-11	2351-2361	difference	abstract[125]|abstract[127]	giv[125]|giv[127]	_	_
17-12	2362-2363	,	_	_	_	_
17-13	2364-2370	showed	_	_	_	_
17-14	2371-2372	a	abstract[128]	new[128]	_	_
17-15	2373-2384	statistical	abstract[128]	new[128]	_	_
17-16	2385-2397	significance	abstract[128]	new[128]	_	_
17-17	2398-2405	between	abstract[128]	new[128]	_	_
17-18	2406-2408	RA	abstract[128]|organization|person[130]	new[128]|giv|giv[130]	coref|coref|coref|coref	18-12[135_130]|18-37|18-12[135_130]|18-37
17-19	2409-2417	patients	abstract[128]|person[130]	new[128]|giv[130]	_	_
17-20	2418-2421	and	abstract[128]|person[130]	new[128]|giv[130]	_	_
17-21	2422-2429	healthy	abstract[128]|person[130]|person[131]	new[128]|giv[130]|giv[131]	coref	19-43[158_131]
17-22	2430-2438	subjects	abstract[128]|person[130]|person[131]	new[128]|giv[130]|giv[131]	_	_
17-23	2439-2440	.	_	_	_	_

#Text=There was a trend of difference finding in the β-diversity between patients with the lowest and the highest levels of TNF-α or IL-17A , indicating an association of gut microbiota composition with the inflammatory parameters in RA patients .
18-1	2441-2446	There	_	_	_	_
18-2	2447-2450	was	_	_	_	_
18-3	2451-2452	a	abstract[132]	new[132]	_	_
18-4	2453-2458	trend	abstract[132]	new[132]	_	_
18-5	2459-2461	of	abstract[132]	new[132]	_	_
18-6	2462-2472	difference	abstract[132]|abstract	new[132]|giv	_	_
18-7	2473-2480	finding	_	_	_	_
18-8	2481-2483	in	_	_	_	_
18-9	2484-2487	the	quantity[134]	giv[134]	_	_
18-10	2488-2499	β-diversity	quantity[134]	giv[134]	_	_
18-11	2500-2507	between	quantity[134]	giv[134]	_	_
18-12	2508-2516	patients	quantity[134]|person[135]	giv[134]|giv[135]	coref	18-37[145_135]
18-13	2517-2521	with	quantity[134]|person[135]	giv[134]|giv[135]	_	_
18-14	2522-2525	the	quantity[134]|person[135]	giv[134]|giv[135]	_	_
18-15	2526-2532	lowest	quantity[134]|person[135]	giv[134]|giv[135]	_	_
18-16	2533-2536	and	quantity[134]|person[135]	giv[134]|giv[135]	_	_
18-17	2537-2540	the	quantity[134]|person[135]|abstract[136]	giv[134]|giv[135]|new[136]	_	_
18-18	2541-2548	highest	quantity[134]|person[135]|abstract[136]	giv[134]|giv[135]|new[136]	_	_
18-19	2549-2555	levels	quantity[134]|person[135]|abstract[136]	giv[134]|giv[135]|new[136]	_	_
18-20	2556-2558	of	quantity[134]|person[135]|abstract[136]	giv[134]|giv[135]|new[136]	_	_
18-21	2559-2564	TNF-α	quantity[134]|person[135]|abstract[136]|abstract	giv[134]|giv[135]|new[136]|giv	_	_
18-22	2565-2567	or	quantity[134]|person[135]|abstract[136]	giv[134]|giv[135]|new[136]	_	_
18-23	2568-2574	IL-17A	quantity[134]|person[135]|abstract[136]|abstract	giv[134]|giv[135]|new[136]|giv	_	_
18-24	2575-2576	,	_	_	_	_
18-25	2577-2587	indicating	_	_	_	_
18-26	2588-2590	an	abstract[139]	new[139]	_	_
18-27	2591-2602	association	abstract[139]	new[139]	_	_
18-28	2603-2605	of	abstract[139]	new[139]	_	_
18-29	2606-2609	gut	abstract[139]|abstract|abstract[142]	new[139]|giv|giv[142]	coref|coref|coref|coref	19-9[148_142]|23-14|19-9[148_142]|23-14
18-30	2610-2620	microbiota	abstract[139]|substance|abstract[142]	new[139]|giv|giv[142]	coref	19-13[149_0]
18-31	2621-2632	composition	abstract[139]|abstract[142]	new[139]|giv[142]	_	_
18-32	2633-2637	with	abstract[139]|abstract[142]	new[139]|giv[142]	_	_
18-33	2638-2641	the	abstract[139]|abstract[142]|abstract[143]	new[139]|giv[142]|new[143]	_	_
18-34	2642-2654	inflammatory	abstract[139]|abstract[142]|abstract[143]	new[139]|giv[142]|new[143]	_	_
18-35	2655-2665	parameters	abstract[139]|abstract[142]|abstract[143]	new[139]|giv[142]|new[143]	_	_
18-36	2666-2668	in	abstract[139]|abstract[142]|abstract[143]	new[139]|giv[142]|new[143]	_	_
18-37	2669-2671	RA	abstract[139]|abstract[142]|abstract[143]|organization|person[145]	new[139]|giv[142]|new[143]|giv|giv[145]	coref|coref|coref|coref	19-39|19-39[157_145]|19-39|19-39[157_145]
18-38	2672-2680	patients	abstract[139]|abstract[142]|abstract[143]|person[145]	new[139]|giv[142]|new[143]|giv[145]	_	_
18-39	2681-2682	.	_	_	_	_

#Text=Using pre-trained Naive Bayes Greengenes classifier to explore the taxonomic composition of gut microbiota , we observed an increased abundance of phylum Verrucomicrobiae , which might be driven by the genus Akkermansia ( Akkermansia muciniphila ) , in RA patients compared with healthy subjects .
19-1	2683-2688	Using	_	_	_	_
19-2	2689-2700	pre-trained	_	_	_	_
19-3	2701-2706	Naive	abstract[147]	new[147]	_	_
19-4	2707-2712	Bayes	place[146]|abstract[147]	new[146]|new[147]	_	_
19-5	2713-2723	Greengenes	place[146]|abstract[147]	new[146]|new[147]	_	_
19-6	2724-2734	classifier	abstract[147]	new[147]	_	_
19-7	2735-2737	to	_	_	_	_
19-8	2738-2745	explore	_	_	_	_
19-9	2746-2749	the	abstract[148]	giv[148]	_	_
19-10	2750-2759	taxonomic	abstract[148]	giv[148]	_	_
19-11	2760-2771	composition	abstract[148]	giv[148]	_	_
19-12	2772-2774	of	abstract[148]	giv[148]	_	_
19-13	2775-2778	gut	abstract[148]|substance[149]	giv[148]|giv[149]	coref	23-13[186_149]
19-14	2779-2789	microbiota	abstract[148]|substance[149]	giv[148]|giv[149]	_	_
19-15	2790-2791	,	_	_	_	_
19-16	2792-2794	we	person	giv	ana	20-1
19-17	2795-2803	observed	_	_	_	_
19-18	2804-2806	an	abstract[151]	new[151]	_	_
19-19	2807-2816	increased	abstract[151]	new[151]	_	_
19-20	2817-2826	abundance	abstract[151]	new[151]	_	_
19-21	2827-2829	of	abstract[151]	new[151]	_	_
19-22	2830-2836	phylum	abstract[151]|person|object[153]	new[151]|giv|giv[153]	coref|coref	23-25|23-25
19-23	2837-2853	Verrucomicrobiae	abstract[151]|object[153]	new[151]|giv[153]	_	_
19-24	2854-2855	,	_	_	_	_
19-25	2856-2861	which	_	_	_	_
19-26	2862-2867	might	_	_	_	_
19-27	2868-2870	be	_	_	_	_
19-28	2871-2877	driven	_	_	_	_
19-29	2878-2880	by	_	_	_	_
19-30	2881-2884	the	abstract[155]	giv[155]	coref	20-11[163_155]
19-31	2885-2890	genus	abstract|abstract[155]	giv|giv[155]	_	_
19-32	2891-2902	Akkermansia	abstract[155]	giv[155]	_	_
19-33	2903-2904	(	_	_	_	_
19-34	2905-2916	Akkermansia	_	_	_	_
19-35	2917-2928	muciniphila	_	_	_	_
19-36	2929-2930	)	_	_	_	_
19-37	2931-2932	,	_	_	_	_
19-38	2933-2935	in	_	_	_	_
19-39	2936-2938	RA	organization|person[157]	giv|giv[157]	coref|coref|coref|coref	23-19[187_0]|23-30[191_157]|23-19[187_0]|23-30[191_157]
19-40	2939-2947	patients	person[157]	giv[157]	_	_
19-41	2948-2956	compared	_	_	_	_
19-42	2957-2961	with	_	_	_	_
19-43	2962-2969	healthy	person[158]	giv[158]	_	_
19-44	2970-2978	subjects	person[158]	giv[158]	_	_
19-45	2979-2980	.	_	_	_	_

#Text=Our findings support the results revealing that the implication of Akkermansia muciniphila in the pathogenesis of murine model of arthritis .
20-1	2981-2984	Our	person|abstract[160]	giv|giv[160]	ana|ana	23-34|23-34
20-2	2985-2993	findings	abstract[160]	giv[160]	_	_
20-3	2994-3001	support	_	_	_	_
20-4	3002-3005	the	abstract[161]	giv[161]	_	_
20-5	3006-3013	results	abstract[161]	giv[161]	_	_
20-6	3014-3023	revealing	_	_	_	_
20-7	3024-3028	that	_	_	_	_
20-8	3029-3032	the	abstract[162]	new[162]	_	_
20-9	3033-3044	implication	abstract[162]	new[162]	_	_
20-10	3045-3047	of	abstract[162]	new[162]	_	_
20-11	3048-3059	Akkermansia	abstract[162]|abstract[163]	new[162]|giv[163]	coref	21-1[0_163]
20-12	3060-3071	muciniphila	abstract[162]|abstract[163]	new[162]|giv[163]	_	_
20-13	3072-3074	in	_	_	_	_
20-14	3075-3078	the	abstract[164]	new[164]	_	_
20-15	3079-3091	pathogenesis	abstract[164]	new[164]	_	_
20-16	3092-3094	of	abstract[164]	new[164]	_	_
20-17	3095-3101	murine	abstract[164]|animal|abstract[166]	new[164]|new|new[166]	coref|coref	26-15|26-15
20-18	3102-3107	model	abstract[164]|abstract[166]	new[164]|new[166]	_	_
20-19	3108-3110	of	abstract[164]|abstract[166]	new[164]|new[166]	_	_
20-20	3111-3120	arthritis	abstract[164]|abstract[166]|abstract	new[164]|new[166]|new	coref	26-18
20-21	3121-3122	.	_	_	_	_

#Text=Akkermansia has also been associated with the proinflammatory pathways , including upregulation of B- and T-cell receptor signaling .
21-1	3123-3134	Akkermansia	abstract	giv	_	_
21-2	3135-3138	has	_	_	_	_
21-3	3139-3143	also	_	_	_	_
21-4	3144-3148	been	_	_	_	_
21-5	3149-3159	associated	_	_	_	_
21-6	3160-3164	with	_	_	_	_
21-7	3165-3168	the	place[169]	new[169]	_	_
21-8	3169-3184	proinflammatory	place[169]	new[169]	_	_
21-9	3185-3193	pathways	place[169]	new[169]	_	_
21-10	3194-3195	,	place[169]	new[169]	_	_
21-11	3196-3205	including	place[169]	new[169]	_	_
21-12	3206-3218	upregulation	place[169]|abstract[170]	new[169]|new[170]	_	_
21-13	3219-3221	of	place[169]|abstract[170]	new[169]|new[170]	_	_
21-14	3222-3224	B-	place[169]|abstract[170]|abstract	new[169]|new[170]|new	_	_
21-15	3225-3228	and	place[169]	new[169]	_	_
21-16	3229-3235	T-cell	place[169]|abstract[173]	new[169]|new[173]	ana	22-8[0_173]
21-17	3236-3244	receptor	place[169]|substance|abstract[173]	new[169]|new|new[173]	_	_
21-18	3245-3254	signaling	place[169]|abstract[173]	new[169]|new[173]	_	_
21-19	3255-3256	.	_	_	_	_

#Text=These proinflammatory effects may be related to its ability to degrade mucus and thus increase the exposure of resident immune cells to gut microbial antigens .
22-1	3257-3262	These	abstract[174]	new[174]	_	_
22-2	3263-3278	proinflammatory	abstract[174]	new[174]	_	_
22-3	3279-3286	effects	abstract[174]	new[174]	_	_
22-4	3287-3290	may	_	_	_	_
22-5	3291-3293	be	_	_	_	_
22-6	3294-3301	related	_	_	_	_
22-7	3302-3304	to	_	_	_	_
22-8	3305-3308	its	abstract|abstract[176]	giv|new[176]	_	_
22-9	3309-3316	ability	abstract[176]	new[176]	_	_
22-10	3317-3319	to	_	_	_	_
22-11	3320-3327	degrade	_	_	_	_
22-12	3328-3333	mucus	object	new	_	_
22-13	3334-3337	and	_	_	_	_
22-14	3338-3342	thus	_	_	_	_
22-15	3343-3351	increase	_	_	_	_
22-16	3352-3355	the	abstract[178]	new[178]	_	_
22-17	3356-3364	exposure	abstract[178]	new[178]	_	_
22-18	3365-3367	of	abstract[178]	new[178]	_	_
22-19	3368-3376	resident	abstract[178]|object[179]	new[178]|new[179]	_	_
22-20	3377-3383	immune	abstract[178]|object[179]	new[178]|new[179]	_	_
22-21	3384-3389	cells	abstract[178]|object[179]	new[178]|new[179]	_	_
22-22	3390-3392	to	_	_	_	_
22-23	3393-3396	gut	_	_	_	_
22-24	3397-3406	microbial	abstract|substance[181]	giv|new[181]	_	_
22-25	3407-3415	antigens	substance[181]	new[181]	_	_
22-26	3416-3417	.	_	_	_	_

#Text=In contrast to previous studies revealing that the predominance of Prevotella in the gut microbiota was associated with the untreated or new-onset RA and phylum Bacteroidetes was enriched in early RA patients , we did not observe significant increase in the abundance of family Prevotellaceae or phylum Bacteroidetes .
23-1	3418-3420	In	_	_	_	_
23-2	3421-3429	contrast	_	_	_	_
23-3	3430-3432	to	_	_	_	_
23-4	3433-3441	previous	abstract[182]	new[182]	_	_
23-5	3442-3449	studies	abstract[182]	new[182]	_	_
23-6	3450-3459	revealing	_	_	_	_
23-7	3460-3464	that	_	_	_	_
23-8	3465-3468	the	abstract[183]	new[183]	_	_
23-9	3469-3481	predominance	abstract[183]	new[183]	_	_
23-10	3482-3484	of	abstract[183]	new[183]	_	_
23-11	3485-3495	Prevotella	abstract[183]|animal	new[183]|new	_	_
23-12	3496-3498	in	abstract[183]	new[183]	_	_
23-13	3499-3502	the	abstract[183]|substance[186]	new[183]|giv[186]	_	_
23-14	3503-3506	gut	abstract[183]|abstract|substance[186]	new[183]|giv|giv[186]	_	_
23-15	3507-3517	microbiota	abstract[183]|substance[186]	new[183]|giv[186]	_	_
23-16	3518-3521	was	_	_	_	_
23-17	3522-3532	associated	_	_	_	_
23-18	3533-3537	with	_	_	_	_
23-19	3538-3541	the	organization[187]	giv[187]	coref	23-31[0_187]
23-20	3542-3551	untreated	organization[187]	giv[187]	_	_
23-21	3552-3554	or	organization[187]	giv[187]	_	_
23-22	3555-3564	new-onset	organization[187]	giv[187]	_	_
23-23	3565-3567	RA	organization[187]	giv[187]	_	_
23-24	3568-3571	and	_	_	_	_
23-25	3572-3578	phylum	person|object[189]	giv|new[189]	coref|coref|coref|coref	23-47|23-47[198_189]|23-47|23-47[198_189]
23-26	3579-3592	Bacteroidetes	object[189]	new[189]	_	_
23-27	3593-3596	was	_	_	_	_
23-28	3597-3605	enriched	_	_	_	_
23-29	3606-3608	in	_	_	_	_
23-30	3609-3614	early	person[191]	giv[191]	coref	24-4[200_191]
23-31	3615-3617	RA	organization|person[191]	giv|giv[191]	coref	25-6
23-32	3618-3626	patients	person[191]	giv[191]	_	_
23-33	3627-3628	,	_	_	_	_
23-34	3629-3631	we	person	giv	ana	24-11
23-35	3632-3635	did	_	_	_	_
23-36	3636-3639	not	_	_	_	_
23-37	3640-3647	observe	_	_	_	_
23-38	3648-3659	significant	abstract[193]	new[193]	_	_
23-39	3660-3668	increase	abstract[193]	new[193]	_	_
23-40	3669-3671	in	abstract[193]	new[193]	_	_
23-41	3672-3675	the	abstract[193]|abstract[194]	new[193]|new[194]	_	_
23-42	3676-3685	abundance	abstract[193]|abstract[194]	new[193]|new[194]	_	_
23-43	3686-3688	of	abstract[193]|abstract[194]	new[193]|new[194]	_	_
23-44	3689-3695	family	abstract[193]|abstract[194]|person|abstract[196]	new[193]|new[194]|new|new[196]	_	_
23-45	3696-3710	Prevotellaceae	abstract[193]|abstract[194]|abstract[196]	new[193]|new[194]|new[196]	_	_
23-46	3711-3713	or	abstract[193]|abstract[194]	new[193]|new[194]	_	_
23-47	3714-3720	phylum	abstract[193]|abstract[194]|person|object[198]	new[193]|new[194]|giv|giv[198]	_	_
23-48	3721-3734	Bacteroidetes	abstract[193]|abstract[194]|object[198]	new[193]|new[194]|giv[198]	_	_
23-49	3735-3736	.	_	_	_	_

#Text=The differences in patients ’ characteristics and treatment regimens of our enrolled patients may explain this discrepancy .
24-1	3737-3740	The	abstract[199]	new[199]	_	_
24-2	3741-3752	differences	abstract[199]	new[199]	_	_
24-3	3753-3755	in	abstract[199]	new[199]	_	_
24-4	3756-3764	patients	abstract[199]|person[200]|abstract[201]	new[199]|giv[200]|new[201]	coref|coref	24-11[205_200]|24-11[205_200]
24-5	3765-3766	’	abstract[199]|person[200]|abstract[201]	new[199]|giv[200]|new[201]	_	_
24-6	3767-3782	characteristics	abstract[199]|abstract[201]	new[199]|new[201]	_	_
24-7	3783-3786	and	abstract[199]	new[199]	_	_
24-8	3787-3796	treatment	abstract[199]|abstract|abstract[203]	new[199]|new|new[203]	_	_
24-9	3797-3805	regimens	abstract[199]|abstract[203]	new[199]|new[203]	_	_
24-10	3806-3808	of	abstract[199]|abstract[203]	new[199]|new[203]	_	_
24-11	3809-3812	our	abstract[199]|abstract[203]|person|person[205]	new[199]|new[203]|giv|giv[205]	coref|coref	25-5[209_205]|25-5[209_205]
24-12	3813-3821	enrolled	abstract[199]|abstract[203]|person[205]	new[199]|new[203]|giv[205]	_	_
24-13	3822-3830	patients	abstract[199]|abstract[203]|person[205]	new[199]|new[203]|giv[205]	_	_
24-14	3831-3834	may	_	_	_	_
24-15	3835-3842	explain	_	_	_	_
24-16	3843-3847	this	abstract[206]	new[206]	_	_
24-17	3848-3859	discrepancy	abstract[206]	new[206]	_	_
24-18	3860-3861	.	_	_	_	_

#Text=It is interesting that active RA patients have an increased abundance of Collinsella compared with inactive RA patients .
25-1	3862-3864	It	event	new	cata	25-1[0_210]
25-2	3865-3867	is	_	_	_	_
25-3	3868-3879	interesting	_	_	_	_
25-4	3880-3884	that	event[210]	new[210]	ana	26-9[0_210]
25-5	3885-3891	active	person[209]|event[210]	giv[209]|new[210]	_	_
25-6	3892-3894	RA	organization|person[209]|event[210]	giv|giv[209]|new[210]	coref	25-17
25-7	3895-3903	patients	person[209]|event[210]	giv[209]|new[210]	_	_
25-8	3904-3908	have	event[210]	new[210]	_	_
25-9	3909-3911	an	event[210]|abstract[211]	new[210]|new[211]	_	_
25-10	3912-3921	increased	event[210]|abstract[211]	new[210]|new[211]	_	_
25-11	3922-3931	abundance	event[210]|abstract[211]	new[210]|new[211]	_	_
25-12	3932-3934	of	event[210]|abstract[211]	new[210]|new[211]	_	_
25-13	3935-3946	Collinsella	event[210]|abstract[211]|animal	new[210]|new[211]|new	_	_
25-14	3947-3955	compared	_	_	_	_
25-15	3956-3960	with	_	_	_	_
25-16	3961-3969	inactive	person[214]	new[214]	_	_
25-17	3970-3972	RA	organization|person[214]	giv|new[214]	coref	27-15[235_0]
25-18	3973-3981	patients	person[214]	new[214]	_	_
25-19	3982-3983	.	_	_	_	_

#Text=The arthrogenic role of Collinsella has been confirmed both in vivo using a humanized murine model of arthritis and in vitro by a human intestinal epithelium cell-based study . Chen et al. further demonstrated that Collinsella could be transferred to germ-free mice with resultant exacerbation of arthritis in a murine model .
26-1	3984-3987	The	abstract[215]	new[215]	_	_
26-2	3988-3999	arthrogenic	abstract[215]	new[215]	_	_
26-3	4000-4004	role	abstract[215]	new[215]	_	_
26-4	4005-4007	of	abstract[215]	new[215]	_	_
26-5	4008-4019	Collinsella	abstract[215]|person	new[215]|new	coref	26-36
26-6	4020-4023	has	_	_	_	_
26-7	4024-4028	been	_	_	_	_
26-8	4029-4038	confirmed	_	_	_	_
26-9	4039-4043	both	event	giv	_	_
26-10	4044-4046	in	_	_	_	_
26-11	4047-4051	vivo	_	_	_	_
26-12	4052-4057	using	_	_	_	_
26-13	4058-4059	a	abstract[219]	new[219]	coref	26-49[229_219]
26-14	4060-4069	humanized	abstract[219]	new[219]	_	_
26-15	4070-4076	murine	animal|abstract[219]	giv|new[219]	coref	26-50
26-16	4077-4082	model	abstract[219]	new[219]	_	_
26-17	4083-4085	of	abstract[219]	new[219]	_	_
26-18	4086-4095	arthritis	abstract[219]|abstract	new[219]|giv	coref	26-47
26-19	4096-4099	and	_	_	_	_
26-20	4100-4102	in	_	_	_	_
26-21	4103-4108	vitro	_	_	_	_
26-22	4109-4111	by	_	_	_	_
26-23	4112-4113	a	abstract[222]	giv[222]	_	_
26-24	4114-4119	human	abstract[222]	giv[222]	_	_
26-25	4120-4130	intestinal	abstract[222]	giv[222]	_	_
26-26	4131-4141	epithelium	place|abstract[222]	new|giv[222]	_	_
26-27	4142-4152	cell-based	abstract[222]	giv[222]	_	_
26-28	4153-4158	study	abstract[222]	giv[222]	_	_
26-29	4159-4160	.	_	_	_	_
26-30	4161-4165	Chen	person	giv	_	_
26-31	4166-4168	et	_	_	_	_
26-32	4169-4172	al.	_	_	_	_
26-33	4173-4180	further	_	_	_	_
26-34	4181-4193	demonstrated	_	_	_	_
26-35	4194-4198	that	_	_	_	_
26-36	4199-4210	Collinsella	animal	giv	coref	27-9
26-37	4211-4216	could	_	_	_	_
26-38	4217-4219	be	_	_	_	_
26-39	4220-4231	transferred	_	_	_	_
26-40	4232-4234	to	_	_	_	_
26-41	4235-4244	germ-free	animal[225]	new[225]	_	_
26-42	4245-4249	mice	animal[225]	new[225]	_	_
26-43	4250-4254	with	animal[225]	new[225]	_	_
26-44	4255-4264	resultant	animal[225]|abstract[226]	new[225]|new[226]	_	_
26-45	4265-4277	exacerbation	animal[225]|abstract[226]	new[225]|new[226]	_	_
26-46	4278-4280	of	animal[225]|abstract[226]	new[225]|new[226]	_	_
26-47	4281-4290	arthritis	animal[225]|abstract[226]|abstract	new[225]|new[226]|giv	_	_
26-48	4291-4293	in	animal[225]|abstract[226]	new[225]|new[226]	_	_
26-49	4294-4295	a	animal[225]|abstract[226]|abstract[229]	new[225]|new[226]|giv[229]	_	_
26-50	4296-4302	murine	animal[225]|abstract[226]|animal|abstract[229]	new[225]|new[226]|giv|giv[229]	_	_
26-51	4303-4308	model	animal[225]|abstract[226]|abstract[229]	new[225]|new[226]|giv[229]	_	_
26-52	4309-4310	.	_	_	_	_

#Text=These observations suggest a potential role of the Collinsella expansion in the pathogenesis of active RA .
27-1	4311-4316	These	abstract[230]	new[230]	_	_
27-2	4317-4329	observations	abstract[230]	new[230]	_	_
27-3	4330-4337	suggest	_	_	_	_
27-4	4338-4339	a	abstract[231]	new[231]	_	_
27-5	4340-4349	potential	abstract[231]	new[231]	_	_
27-6	4350-4354	role	abstract[231]	new[231]	_	_
27-7	4355-4357	of	abstract[231]	new[231]	_	_
27-8	4358-4361	the	abstract[231]|abstract[233]	new[231]|new[233]	_	_
27-9	4362-4373	Collinsella	abstract[231]|object|abstract[233]	new[231]|giv|new[233]	_	_
27-10	4374-4383	expansion	abstract[231]|abstract[233]	new[231]|new[233]	_	_
27-11	4384-4386	in	abstract[231]|abstract[233]	new[231]|new[233]	_	_
27-12	4387-4390	the	abstract[231]|abstract[233]|abstract[234]	new[231]|new[233]|new[234]	_	_
27-13	4391-4403	pathogenesis	abstract[231]|abstract[233]|abstract[234]	new[231]|new[233]|new[234]	_	_
27-14	4404-4406	of	abstract[231]|abstract[233]|abstract[234]	new[231]|new[233]|new[234]	_	_
27-15	4407-4413	active	abstract[231]|abstract[233]|abstract[234]|organization[235]	new[231]|new[233]|new[234]|giv[235]	_	_
27-16	4414-4416	RA	abstract[231]|abstract[233]|abstract[234]|organization[235]	new[231]|new[233]|new[234]|giv[235]	_	_
27-17	4417-4418	.	_	_	_	_
